More aggressive treatment doesn’t impact quality of life for metastatic colorectal cancer patients

13 Oct 2023
More aggressive treatment doesn’t impact quality of life for metastatic colorectal cancer patients

New research in the October 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that intensive local-regional treatment to remove as much tumour as possible (known as “debulking”), in addition to standard systemic therapy, does not impact overall quality of life significantly for people with metastatic colorectal cancer.

The researchers examined the ongoing ORCHESTRA trial to compare patients treated with standard palliative chemotherapy alone to those who received palliative chemotherapy plus either surgery, ablative therapy, and/or radiotherapy to reduce their tumour burden.

300 patients were randomised to receive standard care or additional intervention.

Significant adverse events were reported in 21% of patients in the standard group and 43% of patients who also received tumour debulking.

However, there were no statistical or clinically relevant differences according to patient-reported outcomes for overall health-related quality of life or fatigue.

“This could mean that the negative impact of complications on quality of life is temporary and eventually balances out with a decrease in tumour-related symptoms after treatment. Patients might also adapt their HRQoL perceptions during the course of their disease and treatment.” explained lead author Lotte Bakkerus, MD, Radboud Institute for Health Sciences, The Netherlands.

“Given the considerable amount of complications from local treatment, we had expected to see a bigger impact on overall and persistent quality of life in the experimental group. The fact that local therapy associated serious side effects did not translate to a noticeable dip in the patients' perceived quality of life is quite intriguing and warrants further exploration. These results, including the risk of complications, should be taken into account in the consultation room in order to decide, together with the patient, what the right treatment choice is for each individual.”

The study focused on the results from a preplanned exploratory secondary endpoint of Health-Related Quality of Life (HGQol) from the ORCHESTRA trial, which was measured using the EORTC Quality of Life Questionnaire-Core 30 and the Multidimensional Fatigue Inventory questionnaire at pre-specified time points during treatment.

The intervention group included first-line FOLFOX or CAPOX +/- bevacizumab plus multi-organ debulking to reduce the tumour by at least 80%.

That was compared to the control group of palliative systemic chemo-biologic therapy only.

“Tumour debulking for patients with synchronous oligo-metastatic colorectal cancer is often utilised for curative intent and endorsed in the NCCN Guidelines, with surgical resection preferred over other acceptable treatment modalities such as radiation therapy or thermal ablation. However, the potential survival benefits for such interventions have not been established for patients with multi-organ rather than single-organ colorectal-cancer metastases. That’s a question that the ORCHESTRA trial is attempting to answer,” commented Charles J. Schneider, MD, FACP, Professor of Clinical Medicine in the University of Pennsylvania Perelman School of Medicine and GI Medical Oncologist at Penn Medicine’s Abramson Cancer Center.

Dr. Schneider, is a member of the NCCN Clinical Practice Guidelines in Oncology Panel for Colon/Rectal/Anal Cancers, and was not involved in this study. He continued:

“The outcome of no statistically significant or clinically relevant differences in HRQoL and fatigue after one year was surprising. More intriguing yet, is the fact that although the patients in the intervention group experienced local treatment related serious adverse events (SAEs) twice as often as patients in the standard group, there was a striking lack of association between the occurrence of SAEs and impact on HRQoL. Thus, this HRQoL ‘equivalence,’ even in the face of twice as many SAE’s in the intervention group, should give guarded justification for multi-organ tumour debulking combined with palliative chemotherapy in select patients, if the survival data turns out to favour the intervention group as well.”

Source: National Comprehensive Cancer Network